About Pendulum
Pendulum Therapeutics believes therapies developed using evidence-based microbiome science and DNA sequencing can help heal the body from within. Armed with 13 patents and 42 pending, the company introduced its flagship product Pendulum Glucose Control, a medical probiotic, in 2020 and demonstrated its efficacy in lowering blood sugar spikes and reducing A1C in a published clinical trial. Founded in 2013 by a diverse team of scientists with deep microbiology, biochemistry, computational, and clinical expertise, Pendulum has raised $111 million to date from Meritech Capital, Sequoia Capital, True Ventures, Khosla Ventures, AME Cloud Ventures, and Mayo Clinic among others. Pendulum Therapeutics is headquartered in San Francisco.
Open positions (4)
Company details
Funding
Total raised
$111M
Last stage
Series C
Investors
Founders
John Eid
Led technology development teams for nearly two decades across advanced microscopy, genome sequencing, and biophysical systems. Previously principal scientist at Pacific Biosciences. PhD in Biophysics and Computational Biology from University of Illinois, Urbana-Champaign.
James H. Bullard
Co-founder and CTO of Pendulum Therapeutics. Previously worked at Pacific Biosciences alongside fellow co-founders.
Colleen Cutcliffe
PhD in Biochemistry and Molecular Biology from Johns Hopkins University. Over 20 years of experience in biotech, pharma, and academia. Previously Senior Manager of Biology at Pacific Biosciences.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.